Geert Jan Groeneveld

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4624402/publications.pdf

Version: 2024-02-01

105	2,344	279798	254184
papers	citations	23 h-index	43 g-index

113	113	113	3159
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis. Clinical and Translational Science, 2022, 15, 638-648.	3.1	1
2	Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation. Experimental Brain Research, 2022, 240, 631.	1.5	6
3	A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning <scp>Off</scp> of <scp>AZ</scp>â€009. Movement Disorders, 2022, 37, 790-798.	3.9	8
4	Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLoS ONE, 2022, 17, e0256752.	2.5	17
5	Acute response to cholinergic challenge predicts longâ€term response to galantamine treatment in patients with Alzheimer's disease. British Journal of Clinical Pharmacology, 2022, 88, 2814-2829.	2.4	7
6	Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, doubleâ€blind, placeboâ€controlled, crossâ€over study. British Journal of Clinical Pharmacology, 2022, 88, 2926-2937.	2.4	6
7	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.9	0
8	Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI Insight, 2022, 7, .	5.0	14
9	Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients. Parkinsonism and Related Disorders, 2022, 97, 84-90.	2.2	5
10	A phase I, randomized, doubleâ€blind, placeboâ€controlled, singleâ€and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VXâ€128, a highly selective Na_v1.8 inhibitor, in healthy adults. Clinical and Translational Science, 2022, 15, 981-993.	3.1	4
11	Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placeboâ€controlled</scp>, <scp>doubleâ€blind</scp> phase I/Ib studies in healthy subjects and patients. Clinical and Translational Science, 2022, 15, 2010-2023.	3.1	31
12	Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Study. Clinical Pharmacology and Therapeutics, 2022, 112, 1008-1019.	4.7	1
13	The impact of the global COVIDâ€19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. British Journal of Clinical Pharmacology, 2021, 87, 837-844.	2.4	12
14	Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 33-36.	1.5	5
15	Safety, pharmacokinetics and pharmacodynamics of SBTâ€020 in patients with early stage Huntington's disease, a 2â€part study. British Journal of Clinical Pharmacology, 2021, 87, 2290-2302.	2.4	7
16	Firstâ€inâ€man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M₁â€receptor partial agonist for the treatment of dementias. British Journal of Clinical Pharmacology, 2021, 87, 2945-2955.	2.4	10
17	Spotlight Commentary: Importance of dose redefining in the process of drug repurposing. British Journal of Clinical Pharmacology, 2021, 87, 1705-1707.	2.4	2
18	Tolerance to Opioidâ€Induced Respiratory Depression in Chronic Highâ€Dose Opioid Users: A Modelâ€Based Comparison With Opioidâ€NaÃ¯ve Individuals. Clinical Pharmacology and Therapeutics, 2021, 109, 637-645.	4.7	22

#	Article	IF	Citations
19	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults. Pain Medicine, 2021, 22, 1814-1826.	1.9	13
20	Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 1615.	4.1	6
21	A randomized single and multiple ascending dose study in healthy volunteers of LTIâ€291, a centrally penetrant glucocerebrosidase activator. British Journal of Clinical Pharmacology, 2021, 87, 3561-3573.	2.4	29
22	Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study. Alzheimer's Research and Therapy, 2021, 13, 87.	6.2	11
23	Intronic Haplotypes in <scp>GBA</scp> Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup. Movement Disorders, 2021, 36, 1468-1470.	3.9	1
24	Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 â€acetylcholine receptor agonist: A randomized crossâ€over trial. British Journal of Clinical Pharmacology, 2021, 87, 4439-4449.	2.4	1
25	Firstâ€inâ€human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STRâ€324, a dual enkephalinase inhibitor for pain management. British Journal of Clinical Pharmacology, 2021, , .	2.4	4
26	Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies. Medicine in Drug Discovery, 2021, 10, 100083.	4.5	9
27	Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects. Drugs in R and D, 2021, 21, 295-304.	2.2	4
28	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. Alzheimer's Research and Therapy, 2021, 13, 132.	6.2	4
29	Biperiden Challenge Model in Healthy Elderly as Proofâ€ofâ€Pharmacology Tool: A Randomized, Placeboâ€Controlled Trial. Journal of Clinical Pharmacology, 2021, 61, 1466-1478.	2.0	7
30	False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance. Scientific Reports, 2021, 11, 161.	3.3	2
31	Touchscreen-based finger tapping: Repeatability and configuration effects on tapping performance. PLoS ONE, 2021, 16, e0260783.	2.5	5
32	Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial. JMIR Formative Research, 2021, 5, e31890.	1.4	3
33	Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?. Pharmacogenomics Journal, 2020, 20, 220-226.	2.0	14
34	<scp>DNL</scp>104, a Centrally Penetrant <scp>RIPK</scp>1 Inhibitor, Inhibits <scp>RIP</scp>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2020, 107, 406-414.	4.7	48
35	Parasitic pharmacology: A plausible mechanism of action for cannabidiol. British Journal of Clinical Pharmacology, 2020, 86, 189-191.	2.4	14
36	Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on dropâ€seizure frequency. British Journal of Clinical Pharmacology, 2020, 86, 380-385.	2.4	15

#	Article	IF	Citations
37	Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population. Annals of Neurology, 2020, 87, 154-155.	5.3	1
38	Lack of Detection of the Analgesic Properties of PFâ€05089771, a Selective Na_v1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects. Clinical and Translational Science, 2020, 13, 318-324.	3.1	32
39	Methylphenidate and galantamine in patients with vascular cognitive impairmentâ€“the proof-of-principle study STREAM-VCI. Alzheimer's Research and Therapy, 2020, 12, 10.	6.2	10
40	Safety, pharmacokinetics, and pharmacodynamics of Glnâ€1062, a prodrug of galantamine. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12093.	3.7	9
41	Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation. Pharmacological Reviews, 2020, 72, 899-909.	16.0	30
42	Brain Bio-Energetic State Does Not Correlate to Muscle Mitochondrial Function in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 335-344.	1.9	1
43	Challenging the challenge: A randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development. Brain, Behavior, and Immunity, 2020, 88, 515-528.	4.1	13
44	Utility of Animal Models to Understand Human Alzheimerâ€™s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. International Journal of Molecular Sciences, 2020, 21, 3158.	4.1	12
45	A <scp>Largeâ€Scale</scp> Full <scp>GBA1</scp> Gene Screening in Parkinson's Disease in the Netherlands. Movement Disorders, 2020, 35, 1667-1674.	3.9	41
46	Finding Suitable Clinical Endpoints for a Potential Treatment of a Rare Genetic Disease: the Case of ARID1B. Neurotherapeutics, 2020, 17, 1300-1310.	4.4	10
47	Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy. Brain Research, 2020, 1730, 146621.	2.2	7
48	Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinsonâ€™s disease: a comparative study. Journal of Clinical Movement Disorders, 2020, 7, 4.	2.2	24
49	Simultaneous tracking of psychophysical detection thresholds and evoked potentials to study nociceptive processing. Behavior Research Methods, 2020, 52, 1617-1628.	4.0	16
50	Pharmacodynamic Evaluation: Pain Methodologies. , 2020, , 95-125.		0
51	The Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints. Handbook of Experimental Pharmacology, 2019, 260, 371-397.	1.8	17
52	Analgesic potential of PF-06372865, an Î±2/Î±3/Î±5 subtype-selective GABAA partial agonist, in humans. British Journal of Anaesthesia, 2019, 123, e194-e203.	3.4	20
53	No synergistic effect of subtherapeutic doses of donepezil and EVPâ€6124 in healthy elderly subjects in a scopolamine challenge model. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 89-98.	3.7	8
54	A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development. Journal of Visualized Experiments, 2019, , .	0.3	3

#	Article	IF	Citations
55	Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs. European Journal of Pain, 2019, 23, 1129-1140.	2.8	12
56	Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized doubleâ€blind, placeboâ€controlled crossâ€over trial. CNS Neuroscience and Therapeutics, 2019, 25, 697-703.	3.9	13
57	The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects. European Journal of Pain, 2019, 23, 874-883.	2.8	9
58	The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 21-29.	0.6	30
59	Comparable rates of simulator sickness in Huntingtonâ€™s disease and healthy individuals. Transportation Research Part F: Traffic Psychology and Behaviour, 2019, 60, 499-504.	3.7	4
60	Predictors of simulated driving performance in Huntington's disease. Parkinsonism and Related Disorders, 2019, 60, 64-69.	2.2	7
61	Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Trial. Clinical Pharmacology and Therapeutics, 2018, 104, 1136-1145.	4.7	36
62	Effect profile of paracetamol, Î”9â€<scp>THC</scp> and promethazine using an evoked pain test battery in healthy subjects. European Journal of Pain, 2018, 22, 1331-1342.	2.8	14
63	Glutathioneâ€PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a firstâ€inâ€human study. British Journal of Clinical Pharmacology, 2018, 84, 1020-1028.	2.4	25
64	Reversal of mecamylamineâ€induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. British Journal of Clinical Pharmacology, 2018, 84, 888-899.	2.4	10
65	Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Î”9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. Clinical Therapeutics, 2018, 40, 1467-1482.	2.5	59
66	P1â€016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.8	0
67	H56â€…Driving performance of huntingtonâ€™s disease gene carriers. , 2018, , .		0
68	An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds. Clinical Neurophysiology, 2018, 129, 2325-2332.	1.5	8
69	Altered driving performance of symptomatic Huntingtonâ€™s disease gene carriers in simulated road conditions. Traffic Injury Prevention, 2018, 19, 708-714.	1.4	4
70	Pharmacodynamic Evaluation: Pain Methodologies. , 2018, , 1-31.		2
71	Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 573-580.	2.5	2
72	Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Molecular Pain, 2018, 14, 174480691879704.	2.1	26

#	Article	IF	Citations
73	Mitochondrial function is impaired in the skeletal muscle of pre-frail elderly. Scientific Reports, 2018, 8, 8548.	3.3	76
74	Demonstration of an antiâ€hyperalgesic effect of a novel panâ€Trk inhibitor PFâ€06273340 in a battery of human evoked pain models. British Journal of Clinical Pharmacology, 2018, 84, 301-309.	2.4	34
75	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Research Protocols, 2018, 7, e80.	1.0	3
76	Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties. British Journal of Clinical Pharmacology, 2017, 83, 751-763.	2.4	16
77	Relationships Between Type 2 Diabetes, Neuropathy, and Microvascular Dysfunction: Evidence From Patients With Cryptogenic Axonal Polyneuropathy. Diabetes Care, 2017, 40, 583-590.	8.6	16
78	An antiâ€nicotinic cognitive challenge model using mecamylamine in comparison with the antiâ€muscarinic cognitive challenge using scopolamine. British Journal of Clinical Pharmacology, 2017, 83, 1676-1687.	2.4	13
79	Pharmacokinetics and pharmacodynamics of oral mecamylamine â€“ development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. Journal of Psychopharmacology, 2017, 31, 192-203.	4.0	5
80	Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers. Anesthesiology, 2017, 126, 697-707.	2.5	49
81	The use of a battery of pain models to detect analgesic properties of compounds: a twoâ€part fourâ€way crossover study. British Journal of Clinical Pharmacology, 2017, 83, 976-990.	2.4	30
82	No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery. European Journal of Pain, 2017, 21, 494-506.	2.8	6
83	Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo-controlled proof-of-pharmacology study. European Journal of Pharmacology, 2017, 815, 290-297.	3.5	13
84	EEG machine learning for accurate detection of cholinergic intervention and Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 5775.	3.3	65
85	Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. British Journal of Clinical Pharmacology, 2017, 83, 721-731.	2.4	16
86	Modelâ€based exposureâ€response analysis to quantify age related differences in the response to scopolamine in healthy subjects. British Journal of Clinical Pharmacology, 2016, 82, 1011-1021.	2.4	20
87	Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with antiâ€hyperalgesic effects, in patients with sciatica. British Journal of Clinical Pharmacology, 2016, 82, 108-117.	2.4	18
88	A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models. British Journal of Clinical Pharmacology, 2016, 82, 903-922.	2.4	37
89	Measuring bloodâ€“brain barrier penetration using the NeuroCart, a CNS test battery. Drug Discovery Today: Technologies, 2016, 20, 27-34.	4.0	43
90	Responsiveness of electrical nociceptive detection thresholds to capsaicin (8Â%)-induced changes in nociceptive processing. Experimental Brain Research, 2016, 234, 2505-2514.	1.5	18

#	Article	IF	Citations
91	Quantifying Betaâ€Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling. Clinical and Translational Science, 2016, 9, 321-327.	3.1	5
92	Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery. Journal of Visualized Experiments, 2016, , .	0.3	12
93	19th biennial IPEG Meeting. Neuropsychiatric Electrophysiology, 2016, 2, .	4.1	0
94	Parametric Binding Images of the TSPO Ligand ¹⁸F-DPA-714. Journal of Nuclear Medicine, 2016, 57, 1543-1547.	5.0	23
95	First in human study with a prodrug of galantamine: Improved benefitâ€risk ratio?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 13-22.	3.7	14
96	The Use of Biomarkers in Human Pharmacology (Phase I) Studies. Annual Review of Pharmacology and Toxicology, 2015, 55, 55-74.	9.4	45
97	Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innovations in Clinical Neuroscience, 2015, 12, 5S-10S.	0.1	2
98	P1-368: EFFECT ON MEMORY AND ATTENTION OF TWO DOSES OF MEMOGAIN, A PRODRUG OF GALANTAMINE, IN HEALTHY SUBJECTS. , 2014, 10, P449-P450.		0
99	Fentanyl Utility Function. Anesthesiology, 2013, 119, 663-674.	2.5	36
100	A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease. New England Journal of Medicine, 2010, 362, 1396-1406.	27.0	674
101	Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Annals of Neurology, 2009, 66, 227-234.	5.3	111
102	Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype. Biopharmaceutics and Drug Disposition, 2008, 29, 139-144.	1.9	10
103	An Association Study of Riluzole Serum Concentration and Survival and Disease Progression in Patients With ALS. Clinical Pharmacology and Therapeutics, 2008, 83, 718-722.	4.7	26
104	Alternative trial design in amyotrophic lateral sclerosis saves time and patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 266-269.	2.1	9
105	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. British Journal of Clinical Pharmacology, 2005, 59, 310-313.	2.4	35